112028-91-8 Usage
Description
Diphenylmethyl 7beta-Tert-Butoxycarbonylamino-3-Chloromethyl-3-Cephem-4-Carboxylate is a complex organic compound that belongs to the family of Cephalosporins and Beta-lactams, which are a group of antibiotics derived from fungi. It is a specific type of cephalosporin that is modified to possess a chloromethyl group and a carboxylate functional group, suggesting its unique physiochemical properties and potential pharmacological activities. Its role is typically involved in pharmaceutical research and drug development, indicating its importance within the biotech and health industries.
Uses
Used in Pharmaceutical Research:
Diphenylmethyl 7beta-Tert-Butoxycarbonylamino-3-Chloromethyl-3-Cephem-4-Carboxylate is used as a research compound for the development of new antibiotics. Its unique structure and functional groups may offer novel pharmacological activities and potential applications in the treatment of bacterial infections.
Used in Drug Development:
In the pharmaceutical industry, Diphenylmethyl 7beta-Tert-Butoxycarbonylamino-3-Chloromethyl-3-Cephem-4-Carboxylate is used as a key intermediate in the synthesis of new cephalosporin-based drugs. Its presence in the molecular structure may contribute to enhanced antimicrobial properties or improved drug delivery systems.
Used in Biotech Applications:
Diphenylmethyl 7beta-Tert-Butoxycarbonylamino-3-Chloromethyl-3-Cephem-4-Carboxylate is used as a biotechnological tool in the study of cephalosporin biosynthesis and modification. Its unique features may provide insights into the development of novel biocatalytic processes or the engineering of new biosynthetic pathways for the production of advanced antibiotics.
Note: The specific uses and applications of Diphenylmethyl 7beta-Tert-Butoxycarbonylamino-3-Chloromethyl-3-Cephem-4-Carboxylate may vary depending on the research context and the objectives of the pharmaceutical or biotech project. The information provided here is based on the general understanding of its role in the development of cephalosporin-based drugs and its potential applications in related fields.
Check Digit Verification of cas no
The CAS Registry Mumber 112028-91-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,0,2 and 8 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 112028-91:
(8*1)+(7*1)+(6*2)+(5*0)+(4*2)+(3*8)+(2*9)+(1*1)=78
78 % 10 = 8
So 112028-91-8 is a valid CAS Registry Number.
112028-91-8Relevant articles and documents
Ultrasonic-Assisted Synthesis of Two t -Butoxycarbonylamino Cephalosporin Intermediates on SiO2
Xue, Feng,Wei, Yibin,Ju, Shengui,Xing, Weihong
, (2016/11/07)
Herein, we describe a facile and high efficient strategy for the synthesis of two forms of the 7β-t-butoxycarbonylamino-3-chloromethyl-3-cephem-4-carboxylates using ultrasonic irradiation. By SiO2 as weak Lewis acid catalyst, 4-methoxybenzyl 7β-t-butoxycarbonylamino-3-chloromethyl-3-cephem-carboxylate (Boc-ACLE) and benzhydryl 7β-t-butoxycarbonylamino-3-chloromethyl-3-cephem-4-carboxylate (Boc-ACLH) were successfully synthesized through the efficient protection of the N-t-butoxycarbonyl (N-Boc), and the reactions occurred at low temperature requiring short reaction times and exhibiting excellent isolated yields (96% and 96.2%, resp.). The advantages of this reaction route including the usage of economical reagents and mild reaction conditions and high isolated yield make the two significant t-butoxycarbonylamino cephalosporin intermediates possible in large-scale production.
Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone
Albrecht,Beskid,Christenson,Deitcher,Georgopapadakou,Keith,Konzelmann,Pruess,Chung Chen Wei
, p. 400 - 407 (2007/10/02)
We have previously reported that linking quinolones to the cephalosporin 3'-position through an ester bond, a carbamate function, or a bond through a quaternary nitrogen produced cephalosporins with a dual mode of antibacterial action. We now describe a n
